Frederic Roch Doliveux

Functions as a College/University

Operates as a trade association which promotes pharmaceutical discovery and development

Develops, markets and supplies therapeutic products

Functions as a College/University

Operates as pharmaceutical industry

Manufactures and sells pharmaceuticals and health care products

Provides health care services

Provides research and development services

Part of Pierre Fabre Participations SAS, Pierre Fabre Pharmaceuticals, Inc. is a company that offers Hemangeol, an FDA-approved oral propranolol hydrochloride solution formulated to treat proliferating infantile hemangioma, a common benign vascular tumor in infants that may require systemic therapy to prevent complications affecting vision, breathing, or feeding. The company is based in Parsippany, NJ. The product is designed for infants, featuring a strawberry-vanilla flavor and is free of alcohol, sugar, and parabens, and is supplied with a child-resistant dosing syringe. Treatment typically begins between 5 weeks and 5 months of age and continues for about six months, with weight-based dosing administered twice daily during or after feeding. Safety information includes contraindications such as premature infants under five weeks corrected age, low body weight, asthma, certain cardiac conditions, and propranolol allergy, with potential side effects including hypoglycemia, bradycardia, hypotension, bronchospasm, cardiac failure, increased stroke risk in certain conditions, and hypersensitivity reactions. Common side effects are sleep disturbances, respiratory infections, diarrhea, and vomiting. The product includes dosing charts, calculators, and caregiver support tools to assist with treatment adherence and monitoring. Pierre Fabre Pharmaceuticals provides resources for healthcare professionals, pharmacists, and caregivers, including prescribing information, safety guidelines, educational materials, and patient assistance programs, and collaborates with patient advocacy groups to enhance education and support for families managing infantile hemangiomas.